Q-Motor, a promising motor-assessment tool for adults with Huntington’s disease, also provides non-invasive, easy, and sensitive measures to gauge motor function changes in children and adolescents, a study shows. The data highlights Q-Motor’s potential to detect subtle motor changes associated with Huntington’s disease in at-risk youth. The study, “…
PIGBOS — a newly discovered mitochondrial microprotein involved in a cellular stress-response mechanism called unfolded protein response (UPR) — might be a treatment target for neurodegenerative diseases like Huntington’s, a study suggests. The study, “Regulation of the ER stress response by a mitochondrial microprotein,” was published…
Age of onset in Huntington’s disease is associated with a property of the inherited CAG repeat length in the huntingtin (HTT) gene — which determines the probability of further repeat expansions in nerve cells — rather than with the toxicity of the protein it produces, a study suggests. Along…
Psychiatric and cognitive symptoms in Huntington’s disease share genetic traits with psychiatric disorders and intelligence, respectively, according to a study. These findings suggest that current treatments used for depression and psychotic symptoms in the overall population may also be able to treat these symptoms in Huntington’s patients. The…
Eligible Huntington’s disease patients would likely participate in a gene therapy trial regardless of the study design, but they are more inclined toward those with less invasive interventions and without a placebo group, a questionnaire-based study suggests. The results may be useful to design more patient-centered clinical trials assessing…
Taking care of parents with Huntington’s disease evokes thoughts of “this could be me” in young caregivers and affects their planning for predictive genetic testing, a study shows. The study, ““This could be me”: exploring the impact of genetic risk for Huntington’s disease young caregivers,” was published in…
Potential immunotherapies are showing some positive early results in clinical and preclinical tests, and may offer hope to treat Huntington’s disease, according to a recent review published in the journal Molecular Psychiatry. The review is titled “Are immunotherapies for Huntington’s disease a realistic option?” Huntington’s is…
Cannabinoids can help to treat motor symptoms like dystonia in patients with early-onset Huntington’s disease, a small case study reports. The study, “Cannabinoids for Treatment of Dystonia in Huntington’s Disease,” appeared in the Journal of Huntington’s Disease. Huntington’s disease is characterized by movement disorders, cognitive deterioration,…
Ionis Pharmaceuticals‘ experimental therapy IONIS-HTTRx significantly reduced levels of the protein responsible for Huntington’s disease (HD) in early stage patients, according to top-line results from a Phase 1/2 clinical trial. The data, presented at the 13th Annual HD Therapeutics Conference in Palm Springs, California, confirm IONIS-HTTRx…
Get regular updates to your inbox.